Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Transcenta Therapeutics (hangzhou) Co., Ltd.

Clinical trials sponsored by Transcenta Therapeutics (hangzhou) Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Can a new antibody rebuild bone in osteoporosis? Results expected Apr 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1

Can a new antibody rebuild bone in osteoporosis?

Disease control Not yet recruiting

This phase II trial tests an investigational drug called TST002 in postmenopausal women aged 45 to 80 who have osteoporosis or low bone mass. The study compares three different doses of TST002 against a placebo and an existing osteoporosis drug, denosumab. The main goal is to see…

Phase 2 • Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control

Last updated Sep 09, 2026 18:10 UTC